A systematic review of ambroxol administered intravenously for infant hyaline membrane disease
- Author:
Xiao-Hong CHEN
1
Author Information
1. Department of Pharmacy
- Publication Type:Journal Article
- Keywords:
Ambroxol;
Evidence-based medicine;
Infant hyaline membrane disease;
Meta-analysis;
Neonatal respiratory distress syndrome
- From:
Chinese Pharmaceutical Journal
2012;47(10):771-775
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To systematically review the efficacy and safety of ambroxol administered intravenously for infant hyaline membrane disease. METHODS: The Cochrane collaboration methodology was followed to conduct the systematic review. The Cochrane Library, PubMed, Embase, ISI, CBM, CNKI, VIP, and WanFang Databases were searched. Randomized controlled trails (RCTs) comparing ambroxol administered intravenously with placebo or conventional treatment for HMD were independently selected by two reviewers. The quality of the selected trails was assessed, and the extracted data was analyzed. RESULTS: Seventeen studies involving 1372 cases were included. All the studies were published in Chinese, and the quality scores were C. Meta-analysis showed that ambroxol had statistically significant benefit in reducing HMD incidence rate, HMD death rate, and incidence rate of complication and in increasing the total effective rate and the change of chest x-ray. The RRs (95% CI) were 0.29(0.20, 0.43), 0.24(0.13, 0.45), 0.20(0.11, 0.37), 2.42(1.85, 3.17), and 2.81(2.06, 3.82), respectively. And the ambroxol group also had better outcome than the control group in LOS and mechanical ventilation. Neither of the ambroxol group or the control group had any report of adverse effect. CONCLUSION: Ambroxol given intravenously can effectively reduce the incidence rate, death rate and complications of HMD. It also has good safety. Copyright 2012 by the Chinese Pharmaceutical Association.
